New drug combo aims to stop early blood cancer in its tracks
NCT ID NCT03516617
Summary
This study is for adults with early-stage chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have not yet needed treatment but are at high risk of their disease getting worse. It compares a cancer-fighting pill (acalabrutinib) taken alone to the same pill combined with an immunotherapy drug (obinutuzumab) given by IV. The goal is to see if the two-drug combination is better at controlling the cancer and keeping it from progressing.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mayo Clinic in Arizona
RECRUITINGScottsdale, Arizona, 85259, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Mayo Clinic in Florida
RECRUITINGJacksonville, Florida, 32224-9980, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Mayo Clinic in Rochester
RECRUITINGRochester, Minnesota, 55905, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.